The facility, which is expected to be operational at the end of next year, will produce 10,000 tonnes of each compound per year primarily for the vitamin B3 manufacturing industry as Jubilant CEO Pramod Yadav explained.
“Our decision to set up a new facility for niacinamide reflects our commitment to our customers and vitamin B3 market. Through our in-house research we have developed a very cost efficient and environmental friendly process for the manufacture of these products which will translate into value for our customers.”
For the pharmaceutical industry, the custom research and manufacturing service (CRAMS) firm’s new facility will increase the global supply of key components for a wide range of products, including diabetes treatments and blood pressure drugs.